Infertility Services Market in US 2017-2021


◆タイトル:Infertility Services Market in US 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥490,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥545,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Infertility Services
Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy.

Technavio’s analysts forecast the infertility services market in US to grow at a CAGR of 4.65% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the infertility services market in US for 2017-2021. To calculate the market size, the report considers the services carried out during treatment via infertility drugs and assisted reproductive technology (ART) services.

Technavio’s report, Infertility Services Market in US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CARE facility
• CooperSurgical
• Ferring Pharmaceuticals
• Monash IVF
• Merck
• Vitrolife

[Other prominent vendors]
• AbbVie
• Apricus Biosciences
• AstraZeneca
• Auxogyn
• Eli Lilly
• EMD Serono
• IKS International
• InVitro Care
• INVO Bioscience
• Irvine Scientific
• LifeGlobal
• NMC Health
• OB GYN Associates
• OvaScience
• Pantec Biosolutions
• Reproductive Medicine Associates of New Jersey
• The Sims Clinic
• TriHealth
• Virtus Health
• Xytex Cryo International

[Market driver]
• Rising success rate of infertility treatments.
• For a full, detailed list, view our report

[Market challenge]
• Limited reimbursements and lack of strict regulatory oversight.
• For a full, detailed list, view our report

[Market trend]
• Upsurge in mergers and acquisitions.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

Market overview
Vendor analysis
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by underlying cause

PART 07: Market segmentation by services

Market overview
ART services market in US
Infertility drugs services market in US

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

Competitive scenario
Other prominent vendors

PART 14: Key Vendor Analysis

CARE Fertility
Ferring Pharmaceuticals
Monash IVF

PART 15: Appendix

List of abbreviations

PART 16: Explore Technavio

[List of Exhibits]

Exhibit 01: US infertility services market segmentation: Overview

Exhibit 02: Product offerings

Exhibit 03: Assessment of regulatory bodies

Exhibit 04: Snapshot: Infertility services market in US

Exhibit 05: US fertility chart 2015

Exhibit 06: Stages of infertility treatment

Exhibit 07: Infertility services market in the US 2016-2021 ($ billions)

Exhibit 08: Side effects and success rates of infertility services in US

Exhibit 09: Impact of various factors on infertility services in US

Exhibit 10: Recommendations to vendors

Exhibit 11: Five forces analysis

Exhibit 12: Infertility services market in US by underlying cause

Exhibit 13: Diagnosis of infertility

Exhibit 14: Market segmentation by services 2016-2021(in %)

Exhibit 15: Snapshot: US fertility services market by product

Exhibit 16: Categories of ART services 2016

Exhibit 17: IVF overview

Exhibit 18: ART services market in US 2016-2021 ($ billions)

Exhibit 19: Comparison of fresh and frozen ART cycle

Exhibit 20: Infertility drugs services market in US 2016-2021($ billions)

Exhibit 21: Success rate of IVF procedures

Exhibit 22: ART procedures in US (in thousands)

Exhibit 23: Obesity prevalence in the US (2015)

Exhibit 24: Infertility rates by age

Exhibit 25: US birth rates by women

Exhibit 26: Impact of drivers

Exhibit 27: Cost breakdown of IVF by various stages in US

Exhibit 28: Impact of drivers and challenges

Exhibit 29: Notable M&A activity

Exhibit 30: Same sex married couples in US

Exhibit 31: CARE Fertility: Profile

Exhibit 32: CARE Fertility: Strength analysis

Exhibit 33: CARE Fertility: Strategy assessment

Exhibit 34: CARE Fertility: Opportunity assessment

Exhibit 35: CooperSurgical: Profile

Exhibit 36: CooperSurgical: Strength analysis

Exhibit 37: CooperSurgical: Growth strategy assessment

Exhibit 38: CooperSurgical: Opportunity assessment

Exhibit 39: Ferring Pharmaceuticals: Profile

Exhibit 40: Ferring Pharmaceuticals: Strength analysis

Exhibit 41: Ferring Pharmaceuticals: Strategy assessment

Exhibit 42: Ferring Pharmaceuticals: Opportunity assessment

Exhibit 43: Monash IVF: Profile

Exhibit 44: Monash IVF: Strength analysis

Exhibit 45: Monash IVF: Strategy assessment

Exhibit 46: Monash IVF: Opportunity assessment

Exhibit 47: Merck: Profile

Exhibit 48: Merck: Strength analysis

Exhibit 49: Merck: Strategy assessment

Exhibit 50: Merck: Opportunity assessment

Exhibit 51: Vitrolife: Profile

Exhibit 52: Vitrolife: Strength analysis

Exhibit 53: Vitrolife: Strategy assessment

Exhibit 54: Vitrolife: Opportunity assessment





★調査レポート[不妊治療サービスの米国市場2017-2021] (Infertility Services Market in US 2017-2021 / IRTNTR12046)販売に関する免責事項
[不妊治療サービスの米国市場2017-2021] (Infertility Services Market in US 2017-2021 / IRTNTR12046)についてEメールでお問い合わせ